Summary & Overview

HCPCS Level II J7198: Anti-inhibitor, per i.u.

HCPCS Level II code J7198 designates an anti-inhibitor biologic billed per international unit for management of inhibitor-mediated bleeding in patients with coagulation disorders. This injectable therapy is clinically significant because it addresses antibody-mediated loss of factor activity, often requiring precise dosing and infusion-site resources. Nationally, utilization and payment for anti-inhibitor agents affect specialty pharmacy, hospital outpatient, and payer medical pharmacy budgets.

Key payers in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and common billing practices tied to HCPCS Level II code J7198. The publication summarizes available benchmarks where present, highlights policy and coverage considerations relevant to payers listed above, and outlines operational implications for infusion centers and billing teams.

This article provides practical reference material for revenue cycle, clinical leadership, and payer policy analysts seeking a national perspective on billing, site-of-service expectations, and documentation linked to biologic anti-inhibitor therapy. Data not available in the input will be noted where applicable in detailed sections.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7198HCPCS Level IIAnti-inhibitorInfusion therapyBiologicMedical billingHospital outpatientRevenue cycle

Billing Code Overview

HCPCS Level II code J7198 represents Anti-inhibitor, per international unit (i.u.). The code denotes a biologic therapeutic product used to neutralize inhibitors—antibodies that reduce efficacy—commonly administered for management of bleeding disorders such as hemophilia with inhibitors.

Service Type: Injectable biologic therapy

Typical Site of Service: Hospital outpatient infusion center or ambulatory infusion clinic

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with congenital hemophilia A or B who has developed high-titer inhibitors to factor replacement therapy or a patient with acquired hemophilia presenting with spontaneous or procedure-related bleeding. The patient arrives for infusion of an anti-inhibitor agent billed as J7198 (anti-inhibitor, per i.u.). Prior to infusion, hematology documents indication, inhibitor titer, baseline labs (complete blood count, coagulation panel, inhibitor assay), and informed consent. The infusion typically occurs in an outpatient infusion center, hospital outpatient department, or occasionally inpatient when bleeding is uncontrolled.

The clinical workflow includes:

Referral and pre-authorization for J7198 based on diagnosis and inhibitor status.
Pre-infusion nursing assessment, venous access placement, and verification of weight and ordered international units (I.U.).
Administration of the anti-inhibitor concentrate with vital sign monitoring and documentation of lot number and units administered.
Post-infusion observation for adverse reactions, efficacy assessment (bleeding control), and documentation of any concomitant hemostatic measures.
Billing: units billed using J7198 with appropriate modifier if services, dispensing, or circumstances require reporting (for example, JW for discarded drug, QY for items furnished under DMEPOS competitive bidding if applicable).

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	Use when part of the dispensed anti-inhibitor product is discarded and documentation supports wasted units.
`JZ`	No drug administered, zero drug wasted	Use when product was not administered and nothing was wasted.
`QX`	Service furnished by a practitioner with a prohibited referral relationship	Use to indicate the service was performed by a practitioner subject to the physicians self-referral disclosure exception when required.
`QY`	Item or service furnished under a DMEPOS competitive bidding program	Rare for `J7198` but used if the product was furnished under such a program.
`62`	Two surgeons	Use when co-surgeons are involved for a related procedure requiring both surgeons (rare for infusion itself).
`78`	Return to OR for related procedure during postoperative period	Use when a surgical patient receiving `J7198` requires an unplanned return to the operating room.
`80`	Assistant surgeon	Use when an assistant surgeon is required for an associated operative procedure.
`82`	Assistant surgeon when a qualified resident is not available	Use similarly to `80` when no resident is available.
`52`	Reduced services	Use when the infusion or associated service was partially reduced or not completed as originally planned.
`53`	Discontinued procedure	Use when the infusion or related procedure was started but halted due to clinical reasons.
`55`	Postoperative management only	Use when only postoperative care is billed separately from the infusion or procedure.
`56`	Preoperative management only	Use when only preoperative care is billed separately from the infusion or procedure.
`23`	Unusual anesthesia	Use when unusual anesthesia services are required for a related procedure.
`78`	(duplicate entry avoided above)	(See prior)

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology & Oncology	Hematologists prescribe and oversee anti-inhibitor therapy and coordinate infusions.
`2080P0206X`	Pediatric Hematology-Oncology	Pediatric specialists manage children with hemophilia and inhibitors.
`207K00000X`	Internal Medicine	Hospitalists or internists may manage inpatient infusion and bleeding complications.
`3336C0002X`	Clinical Laboratory Director	Laboratory oversight for inhibitor assays and coagulation testing.
`364S00000X`	Nursing — Infusion Therapy	Infusion nurses administer and monitor anti-inhibitor products.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D66`	Hereditary factor VIII deficiency (Hemophilia A)	Hemophilia A patients who develop inhibitors require anti-inhibitor therapy to control bleeding.
`D67`	Hereditary factor IX deficiency (Hemophilia B)	Hemophilia B patients with inhibitors may need bypassing agents or anti-inhibitor concentrates.
`D68.312`	Acquired hemophilia due to autoantibodies to factor VIII	Acquired inhibitors cause spontaneous bleeding managed with anti-inhibitor therapies.
`T80.7XXA`	Transfusion reaction due to immune response, initial encounter	Relevant when infusion reactions are a concern and monitoring is required; documents adverse events.
`I97.8`	Complications of other procedures, not elsewhere classified	Used when complications from procedures or infusions necessitate additional anti-inhibitor dosing.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, initial, up to 1 hour	Use for billing the initial infusion administration time for the anti-inhibitor product in an outpatient infusion setting.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary service)	Use when infusion time extends beyond the first hour.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Use when a subcutaneous prophylactic hemostatic agent is given in conjunction with `J7198`.
`36415`	Collection of venous blood by venipuncture	Use for pre-infusion laboratory testing such as inhibitor titer and coagulation studies.
`93000`	Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report	Use when monitoring cardiac status is clinically indicated before or during infusion in at-risk patients.
`96374`	Therapeutic, prophylactic, or diagnostic infusion (more than 8 hours)	Use if the infusion protocol requires prolonged administration beyond standard infusion time.